BACKGROUND: Vandetanib (ZACTIMA) is a once-daily oral inhibitor of vascular endothelial growth factor, epidermal growth factor and RET receptor tyrosine kinases. The safety and tolerability of vandetanib plus mFOLFOX6 was investigated in patients with advanced colorectal cancer (CRC). METHODS: Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of mFOLFOX6. RESULTS: Seventeen patients received vandetanib 100 mg (n = 9) or 300 mg (n = 8) plus mFOLFOX6. The protocol definition of a tolerable dose (vandetanib-related dose-limiting toxicity [DLT] in less than two patients) was met in both dose cohorts, with one DLT of diarrhoea reported in each. Overall, the most common adverse events were diarrhoea, nausea and lethargy (all n = 11). There was no pharmacokinetic interaction between vandetanib and mFOLFOX6. Preliminary efficacy results included one complete response and three confirmed partial responses. CONCLUSIONS: In patients with advanced CRC, once-daily vandetanib (100 or 300 mg) with mFOLFOX6 was generally well tolerated.
BACKGROUND: Vandetanib (ZACTIMA) is a once-daily oral inhibitor of vascular endothelial growth factor, epidermal growth factor and RET receptor tyrosine kinases. The safety and tolerability of vandetanib plus mFOLFOX6 was investigated in patients with advanced colorectal cancer (CRC). METHODS: Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of mFOLFOX6. RESULTS: Seventeen patients received vandetanib 100 mg (n = 9) or 300 mg (n = 8) plus mFOLFOX6. The protocol definition of a tolerable dose (vandetanib-related dose-limiting toxicity [DLT] in less than two patients) was met in both dose cohorts, with one DLT of diarrhoea reported in each. Overall, the most common adverse events were diarrhoea, nausea and lethargy (all n = 11). There was no pharmacokinetic interaction between vandetanib and mFOLFOX6. Preliminary efficacy results included one complete response and three confirmed partial responses. CONCLUSIONS: In patients with advanced CRC, once-daily vandetanib (100 or 300 mg) with mFOLFOX6 was generally well tolerated.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: A L Thomas; T Trarbach; C Bartel; D Laurent; A Henry; M Poethig; J Wang; E Masson; W Steward; U Vanhoefer; B Wiedenmann Journal: Ann Oncol Date: 2007-01-11 Impact factor: 32.976
Authors: Brian M Wolpin; Jeffrey W Clark; Jeffrey A Meyerhardt; Craig C Earle; David P Ryan; Peter C Enzinger; Andrew X Zhu; Lawrence Blaszkowsky; Subha Battu; Charles S Fuchs Journal: Clin Colorectal Cancer Date: 2006-09 Impact factor: 4.481
Authors: Petra Kupsch; Bernhard F Henning; Katrin Passarge; Heike Richly; Katrin Wiesemann; Ralf A Hilger; Max E Scheulen; Olaf Christensen; Erich Brendel; Brian Schwartz; Elke Hofstra; Rudolf Voigtmann; Siegfried Seeber; Dirk Strumberg Journal: Clin Colorectal Cancer Date: 2005-09 Impact factor: 4.481
Authors: Bruce J Giantonio; Paul J Catalano; Neal J Meropol; Peter J O'Dwyer; Edith P Mitchell; Steven R Alberts; Michael A Schwartz; Al B Benson Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: S Cascinu; R Berardi; S Salvagni; G D Beretta; V Catalano; F Pucci; A Sobrero; P Tagliaferri; R Labianca; M Scartozzi; F Crocicchio; E Mari; A Ardizzoni Journal: Br J Cancer Date: 2007-12-04 Impact factor: 7.640
Authors: Nicolas Penel; Jean-Pierre Delord; Marie-Edith Bonneterre; Thomas Bachelot; Isabelle Ray-Coquard; Jean-Yves Blay; Laurent Benjamin Pascal; Cécile Borel; Thomas Filleron; Antoine Adenis; Jacques Bonneterre Journal: Invest New Drugs Date: 2009-02-10 Impact factor: 3.850
Authors: Vasiliki A Papadimitrakopoulou; Steven J Frank; Ezra W Cohen; Fred R Hirsch; Jeffrey N Myers; John V Heymach; Heather Lin; Hai T Tran; Changhu R Chen; Antonio Jimeno; Lucien Nedzi; Joseph R Vasselli; Elizabeth S Lowe; David Raben Journal: Head Neck Date: 2015-06-16 Impact factor: 3.147
Authors: Teri N Kreisl; Katharine A McNeill; Joohee Sul; Fabio M Iwamoto; Joanna Shih; Howard A Fine Journal: Neuro Oncol Date: 2012-10-25 Impact factor: 12.300